EBpay

    Stock code: 002653.SZ
    BEICHANGPING® (Cofrogliptin Tablets)
    Drug Introduction

    Officially approved in June 2024, it is the world's first biweekly ultra-long-acting oral hypoglycemic agent, achieving innovative first launch in China. With only 26 doses required per year, it improves patient compliance, enables long-term stable glycemic control, offers high safety, and is not restricted by liver or kidney function, providing long-term benefits to patients and filling the gap in the field of long-acting oral hypoglycemic agents in China.


    References
    [1] Instructions for the Kauglitin tablet medicine.
    [2] Bai N, et al. Diabetes Ther. 2024 Jan;15(1):183-199.
    [3] Pan C, J, et al. Diabetes Obes Metab. 2026 Feb;28(2):1191-1200.
    [4] Gao L, et al. Diabetes Obes Metab. 2025 Jan;27(1):280-290.
    [5] Ren Q, et al. Diabetes Obes Metab. 2024 Nov;26(11):5013-5024.Aschner P, et al. Diabetes Care
    [6] Aschner P, et al. Diabetes Care. 2006 Dec;29(12):2632-7.
    [7] Dejager S, et al. Horm Metab Res. 2007 Mar;39(3):218-23.
    [8]Rosenstock J, et al. Curr Med Res Opin. 2009 Oct;25(10):2401-11.
    [9]Del Prato S, et al. Diabetes Obes Metab. 2011 Mar;13(3):258-67.
    [10] DeFronzo RA, et al. Diabetes Care. 2008 Dec;31(12):2315-7.


    Download prescribing information
    BEICHANGPING® (Cofrogliptin Tablets)
    Once every 2 weeks <sup>[1-2]</sup>

    Once every 2 weeks [1-2]

    Long half-life up to 131.5 h; A single oral dose maintains DPP-4 enzyme inhibition rate above 80% for two weeks
    Stable glycemic control<sup>[3-5]</sup>

    Stable glycemic control[3-5]

    Provides more stable glycemic control compared to daily DPP4 inhibitors; Low risk of hypoglycemia, few side effects, and few drug interactions.
    Hepatic or renal safety <sup>[1]</sup>

    Hepatic or renal safety [1]

    No dose adjustment required for patients with renal insufficiency or mild hepatic insufficiency
    Top-tier Publications, International Recognition

    • 12 Papers in top journals, including Journal of Medicinal Chemistry and Diabetes Obesity & Metabolism, etc.;

    • Presentations at 8 Global Top-tier Conferences such as ADA (American Diabetes Association), EASD (European Association for the Study of Diabetes), and ENDO (The Endocrine Society), showcasing China's original hypoglycemic drug research achievements to the world;

    • Recommended by 7 authoritative guidelines and expert consensus, including Chinese Guideline for Diabetes Prevention and Treatment (2024 Edition) and National Guidelines for Prevention and Management of Diabetes in Primary Care(2025 Edition).


    Successfully included in the National Reimbursement Drug List in 2025; as of May 2026, it has been used in over 6000 medical institutions, cumulatively benefiting over 400,000 400,000 patients.
    Top-tier Publications, International Recognition
    Top-tier Publications, International Recognition
    Frequently Asked Questions
    Common Questions and Answers
    BEICHANGPING® (Cofrogliptin Tablets)Frequently Asked Questions
    Q

    What global first status does Beichangping® (Kaloglitin) have in the field of hypoglycemic drugs?

    A

    It is the world's first bi-weekly ultra-long-acting oral diabetes medication, filling a gap in the domestic market.

    Q

    When was Beichangping® (Kaloglitin) approved?

    A
    It was officially approved in June 2024.
    Q

    What are the core indications for Beichangping® (Caglituzine)?

    A
    Used to improve blood sugar control in adult patients with type 2 diabetes.
    Q

    What is the dosage cycle for Beichangping® (Kaloglitin)?

    A
    Take it once every two weeks.
    Q

    How long is the half-life of Beichangping® (Caglituzine)?

    A
    The long half-life can reach 131.5 hours.
    Q

    How is the enzyme inhibition effect after taking Bailongping® (Kaloglitin)?

    A
    A single oral dose can maintain a DPP-4 enzyme inhibition rate of over 80% for two weeks.
    Q

    Is Bailongping® (Kaloglitin) suitable for patients with impaired liver function?

    A
    Patients with renal insufficiency and mild liver dysfunction do not need to adjust the dosage, ensuring safety.
    Q

    Is the risk of hypoglycemia caused by Bei Chang Ping® (Caglituzine) high?

    A
    Due to its glucose-dependent hypoglycemic mechanism, the risk of hypoglycemia is extremely low.
    Q

    How do the side effects and interactions of Beichangping® (Kaloglitin) manifest?

    A
    The side effects of the drug are minimal, and there are few interactions with other medications.
    Q

    As of May 2026, how many academic papers have been published on Beichangping® (Kaglitide)?

    A
    12 related academic papers have been published so far.
    Q

    In which renowned journals have the related papers on Bialongping® (cosglibetin) been published?

    A
    Including journals such as the Journal of Medicinal Chemistry and Diabetes Obesity & Metabolism.
    Q

    As of May 2026, how many global top academic events has Bei Changping® (Koglitide) attended?

    A
    Has appeared at top global academic conferences 8 times.
    Q

    Which international diabetes conferences has Beichangping® (Kaglitide) appeared at?

    A
    Including ADA (American Diabetes Association), EASD (European Association for Diabetes Research), and ENDO (Endocrine Society of America), etc.
    Q

    What is the presentation format of Beichangping® (Caglitide) at international conferences?

    A
    Present research findings to the world through oral presentations and posters.
    Q

    As of May 2026, how many expert guidelines have included Bei Chang Ping® (kovaglitin)?

    A
    It has been officially included in 7 authoritative guidelines and expert consensus.
    Q

    Which key diabetes guidelines have included Beilongping® (Caglituzine)?

    A
    Including "Chinese Guidelines for Diabetes Prevention and Management (2024 Edition)" and "National Guidelines for Primary Diabetes Prevention and Management (2025 Edition)", etc.
    Q

    What is the medical insurance coverage for Beichangping® (Kaglitide)?

    A
    In 2024, the first medical insurance negotiation was carried out, and in 2025 it was successfully included in the national medical insurance list.
    Q

    As of May 2026, how many hospitals have adopted Beichangping® (Kaglitide)?

    A
    6028 medical institutions across the country have joined and started using these prescriptions.
    Q

    As of May 2026, how many diabetic patients have been benefited by Beichangping® (kovaglitin) in total?

    A
    The number of patients benefiting has reached over 400,000.
    Q

    What is the main advantage of Beichangping® (Caglituzine)?

    A
    It has three core advantages: long-lasting effectiveness, no harm to the liver and kidneys, and stability and peace of mind.
    BEICHANGPING® (Cofrogliptin Tablets): 8 tablets
    Buy Now
    BEICHANGPING® (Cofrogliptin Tablets): 8 tablets